EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: A randomised, double-blind, placebo-controlled phase 2 clinical trial (Lancet, 2014)

(untitled) - Rice, A; Dworkin, R; McCarthy, T; Anand, P; Bountra, C; McCloud, P; Hill, J; Cutter, G; Cutter, G; Kitson, G; Desem, N; Raff, M; et al.